(Q43599415)

English

Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2‑positive breast cancer: an NSABP Foundation Research Program phase I study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 November 2017

Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2‑positive breast cancer: an NSABP Foundation Research Program phase I study (English)

1 reference

Europe PubMed Central

25 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Rachel C Jankowitz

1

1 reference

Europe PubMed Central

25 November 2017

Jame Abraham

2

1 reference

Europe PubMed Central

25 November 2017

Antoinette R Tan

3

1 reference

Europe PubMed Central

25 November 2017

Steven A Limentani

4

1 reference

Europe PubMed Central

25 November 2017

Marni B Tierno

5

1 reference

Europe PubMed Central

25 November 2017

Laura M Adamson

6

1 reference

Europe PubMed Central

25 November 2017

Marc Buyse

7

1 reference

Europe PubMed Central

25 November 2017

Norman Wolmark

8

1 reference

Europe PubMed Central

25 November 2017

Samuel A Jacobs

9

1 reference

Europe PubMed Central

25 November 2017

publication date

1 December 2013

1 reference

Europe PubMed Central

25 November 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

25 November 2017

72

1 reference

Europe PubMed Central

25 November 2017

6

1 reference

Europe PubMed Central

25 November 2017

1205-1212

1 reference

Europe PubMed Central

25 November 2017

https://scigraph.springernature.com/pub.10.1007/s00280-013-2262-2

0 references

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2262-2

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2262-2

21 January 2018

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2262-2

21 January 2018

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2262-2

21 January 2018

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2262-2

21 January 2018

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2262-2

21 January 2018

Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2262-2

21 January 2018

Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2262-2

21 January 2018

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2262-2

21 January 2018

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2262-2

21 January 2018

Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2262-2

21 January 2018

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2262-2

21 January 2018

A genome-wide RNAi screen identifies novel targets of neratinib sensitivity leading to neratinib and paclitaxel combination drug treatments.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2262-2

21 January 2018

Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2262-2

21 January 2018

A single-arm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2262-2

21 January 2018

Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2262-2

21 January 2018

Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2262-2

21 January 2018

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2262-2

21 January 2018

Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2262-2

21 January 2018

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2262-2

21 January 2018

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2262-2

21 January 2018

Comprehensive molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2262-2

21 January 2018

A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2262-2

21 January 2018

Identifiers

10.1007/S00280-013-2262-2

1 reference

Europe PubMed Central

25 November 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

25 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43599415&oldid=2101807227"